References
Kim HJ, Ko YH, Kim JE, Lee SS, Lee H, Park G, Paik JH, Cha HJ, Choi YD, Han JH, Huh J, Hematopathology Study Group of the Korean Society of Pathologists (2017) Epstein-Barr virus-associated lymphoproliferative disorders: review and update on 2016 WHO classification. J Pathol Transl Med 51(4):352–358
Hue SS, Oon ML, Wang S, Tan SY, Ng SB (2020) Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach. Pathology. 52(1):111–127
Pillai V, Tallarico M, Bishop MR, Lim MS (2016) Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents. Br J Haematol 173(4):573–581
Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K (2008) Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99(5):1016–1020
Uno M, Tsuchiyama J, Moriwaki A, Noguchi T, Mizoguchi K, Ogino T, Yoshino T, Okada S, Harada M (2001) In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A. Br J Haematol 113(4):1009–1014
Lee KW, Yun T, Kim DW, Im SA, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK (2006) First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 47(7):1274–1282
Yang L, Liu H, Xu XH, Wang XF, Huang HM, Shi WY, Jiang SH (2013) Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)/T cell lymphoma, nasal type. Med Oncol 30(4):720
Yoshida M, Osumi T, Imadome KI, Tomizawa D, Kato M, Miyazawa N, Ito R, Nakazawa A, Matsumoto K (2018) Successful treatment of systemic EBV positive T-cell lymphoma of childhood using the SMILE regimen. Pediatr Hematol Oncol 35(2):121–124
Acknowledgements
We gratefully acknowledge the pathologists in our hospital for their expertise and generous provision of data. We thank Gillian Campbell, PhD, from Liwen Bianji, Edanz Group China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Statement
The parents of this child provided informed consent for the publication of the case. The study was approved by the ethics and plan review committee of Nanjing Medical University.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
ESM 1
(DOCX 105 kb)
Rights and permissions
About this article
Cite this article
Li, J., Ye, J., Wang, Y. et al. Successful treatment by using a modified SMILE regimen and autologous hematopoietic stem cell transplantation in a pediatric primary EBV-positive nodular NK/T cell lymphoma patient. Ann Hematol 101, 433–435 (2022). https://doi.org/10.1007/s00277-021-04459-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-021-04459-2